Literature DB >> 17846869

Computational models to assign biopharmaceutics drug disposition classification from molecular structure.

Akash Khandelwal1, Praveen M Bahadduri, Cheng Chang, James E Polli, Peter W Swaan, Sean Ekins.   

Abstract

PURPOSE: We applied in silico methods to automatically classify drugs according to the Biopharmaceutics Drug Disposition Classification System (BDDCS).
MATERIALS AND METHODS: Models were developed using machine learning methods including recursive partitioning (RP), random forest (RF) and support vector machine (SVM) algorithms with ChemDraw, clogP, polar surface area, VolSurf and MolConnZ descriptors. The dataset consisted of 165 training and 56 test set molecules.
RESULTS: RF model 3, RP model 1, and SVM model 1 can correctly predict 73.1, 63.6 and 78.6% test compounds in classes 1, 2 and 3, respectively. Both RP and SVM models can be used for class 4 prediction. The inclusion of consensus analysis resulted in improved test set predictions for class 2 and 4 drugs.
CONCLUSIONS: The models can be used to predict BDDCS class for new compounds from molecular structure using readily available molecular descriptors and software, representing an area where in silico approaches could aid the pharmaceutical industry in speeding drugs to the patient and reducing costs. This could have significant applications in drug discovery to identify molecules that may have future developability issues.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17846869     DOI: 10.1007/s11095-007-9435-9

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  158 in total

1.  Summary workshop report: biopharmaceutics classification system--implementation challenges and extension opportunities.

Authors:  James E Polli; Lawrence X Yu; Jack A Cook; Gordon L Amidon; Ronald T Borchardt; Beth A Burnside; Philip S Burton; Mei-Ling Chen; Dale P Conner; Patrick J Faustino; Amale A Hawi; Ajaz S Hussain; Hemant N Joshi; Gloria Kwei; Vincent H L Lee; Lawrence J Lesko; Robert A Lipper; Alice E Loper; Shriniwas G Nerurkar; Joseph W Polli; Dilip R Sanvordeker; Rajneesh Taneja; Ramana S Uppoor; Chandra S Vattikonda; Ian Wilding; Guohua Zhang
Journal:  J Pharm Sci       Date:  2004-06       Impact factor: 3.534

2.  Greater than the sum of its parts: combining models for useful ADMET prediction.

Authors:  Sean E O'Brien; Marcel J de Groot
Journal:  J Med Chem       Date:  2005-02-24       Impact factor: 7.446

3.  Population pharmacokinetics and therapeutic response of CGP 56697 (artemether + benflumetol) in malaria patients.

Authors:  F Ezzet; R Mull; J Karbwang
Journal:  Br J Clin Pharmacol       Date:  1998-12       Impact factor: 4.335

Review 4.  Clinical pharmacology and therapeutic potential of artemisinin and its derivatives in the treatment of malaria.

Authors:  P J de Vries; T K Dien
Journal:  Drugs       Date:  1996-12       Impact factor: 9.546

Review 5.  Clinical pharmacokinetics of sulphasalazine, its metabolites and other prodrugs of 5-aminosalicylic acid.

Authors:  U Klotz
Journal:  Clin Pharmacokinet       Date:  1985 Jul-Aug       Impact factor: 6.447

6.  Identification of CYP3A4 and CYP2C8 as the major cytochrome P450 s responsible for morphine N-demethylation in human liver microsomes.

Authors:  D Projean; P-E Morin; T M Tu; J Ducharme
Journal:  Xenobiotica       Date:  2003-08       Impact factor: 1.908

7.  Involvement of human cytochrome P450 3A4 in reduced haloperidol oxidation.

Authors:  S Kudo; M Odomi
Journal:  Eur J Clin Pharmacol       Date:  1998-05       Impact factor: 2.953

8.  Pilot study on the absolute and relative bioavailability of Synthroid and Levothroid, two brands of sodium levothyroxine.

Authors:  H R Maxon; W A Ritschel; C P Volle; M A Eldon; I W Chen; M F Fernandez; J Cline; G Mayfield
Journal:  Int J Clin Pharmacol Ther Toxicol       Date:  1983-08

9.  Acetaminophen metabolism by cytochrome P450 monooxygenases in Parkinson's disease.

Authors:  S A Factor; W J Weiner; F Hefti
Journal:  Ann Neurol       Date:  1989-08       Impact factor: 10.422

10.  Pharmacokinetics of didanosine in patients with acquired immunodeficiency syndrome or acquired immunodeficiency syndrome-related complex.

Authors:  C A Knupp; W C Shyu; R Dolin; F T Valentine; C McLaren; R R Martin; K A Pittman; R H Barbhaiya
Journal:  Clin Pharmacol Ther       Date:  1991-05       Impact factor: 6.875

View more
  11 in total

1.  The BCS, BDDCS, and regulatory guidances.

Authors:  Mei-Ling Chen; Gordon L Amidon; Leslie Z Benet; Hans Lennernas; Lawrence X Yu
Journal:  Pharm Res       Date:  2011-04-14       Impact factor: 4.200

2.  BDDCS applied to over 900 drugs.

Authors:  Leslie Z Benet; Fabio Broccatelli; Tudor I Oprea
Journal:  AAPS J       Date:  2011-08-05       Impact factor: 4.009

3.  Efficacy of Tilorone Dihydrochloride against Ebola Virus Infection.

Authors:  Sean Ekins; Mary A Lingerfelt; Jason E Comer; Alexander N Freiberg; Jon C Mirsalis; Kathleen O'Loughlin; Anush Harutyunyan; Claire McFarlane; Carol E Green; Peter B Madrid
Journal:  Antimicrob Agents Chemother       Date:  2018-01-25       Impact factor: 5.191

4.  Toward predicting drug-induced liver injury: parallel computational approaches to identify multidrug resistance protein 4 and bile salt export pump inhibitors.

Authors:  Matthew A Welch; Kathleen Köck; Thomas J Urban; Kim L R Brouwer; Peter W Swaan
Journal:  Drug Metab Dispos       Date:  2015-03-03       Impact factor: 3.922

5.  BDDCS class prediction for new molecular entities.

Authors:  Fabio Broccatelli; Gabriele Cruciani; Leslie Z Benet; Tudor I Oprea
Journal:  Mol Pharm       Date:  2012-02-07       Impact factor: 4.939

6.  Identification and validation of novel human pregnane X receptor activators among prescribed drugs via ligand-based virtual screening.

Authors:  Yongmei Pan; Linhao Li; Gregory Kim; Sean Ekins; Hongbing Wang; Peter W Swaan
Journal:  Drug Metab Dispos       Date:  2010-11-10       Impact factor: 3.922

7.  Machine learning methods and docking for predicting human pregnane X receptor activation.

Authors:  Akash Khandelwal; Matthew D Krasowski; Erica J Reschly; Michael W Sinz; Peter W Swaan; Sean Ekins
Journal:  Chem Res Toxicol       Date:  2008-06-12       Impact factor: 3.739

8.  In vitro studies are sometimes better than conventional human pharmacokinetic in vivo studies in assessing bioequivalence of immediate-release solid oral dosage forms.

Authors:  James E Polli
Journal:  AAPS J       Date:  2008-05-24       Impact factor: 4.009

9.  Open Source Bayesian Models. 1. Application to ADME/Tox and Drug Discovery Datasets.

Authors:  Alex M Clark; Krishna Dole; Anna Coulon-Spektor; Andrew McNutt; George Grass; Joel S Freundlich; Robert C Reynolds; Sean Ekins
Journal:  J Chem Inf Model       Date:  2015-06-03       Impact factor: 4.956

10.  Design and Synthesis of Novel Deuterated Ligands Functionally Selective for the γ-Aminobutyric Acid Type A Receptor (GABAAR) α6 Subtype with Improved Metabolic Stability and Enhanced Bioavailability.

Authors:  Daniel E Knutson; Revathi Kodali; Branka Divović; Marco Treven; Michael R Stephen; Nicolas M Zahn; Vladimir Dobričić; Alec T Huber; Matheus A Meirelles; Ranjit S Verma; Laurin Wimmer; Christopher Witzigmann; Leggy A Arnold; Lih-Chu Chiou; Margot Ernst; Marko D Mihovilovic; Miroslav M Savić; Werner Sieghart; James M Cook
Journal:  J Med Chem       Date:  2018-03-06       Impact factor: 8.039

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.